Several of us have reported our CLL symptoms have come roaring back after discontinuing Ibrutinib/imbruvica with even a few cases of what's been termed pseudo-Richters, where some patients appear to have even undergone unnecessary R-CHOP chemoimmunotherapy as our member Priss69 has reported: healthunlocked.com/cllsuppo...
healthunlocked.com/cllsuppo...
healthunlocked.com/cllsuppo...
Per this November, 2020 study report
academic.oup.com/oncolo/art...
with my emphasis:
"Rapid CLL progression following ibrutinib discontinuation has been increasingly recognized. This study demonstrates that similar flares in disease signs or symptoms may occur during ibrutinib holds as well."
Background: Approximately 25% of patients with chronic lymphocytic leukemia (CLL) experience a flare of disease following ibrutinib discontinuation. A critical question is whether this phenomenon may also occur when ibrutinib is temporarily held. This study aimed to determine the frequency and characteristics of disease flares in this setting and assess risk factors and clinical outcomes.
Conclusion: Temporary interruptions in ibrutinib treatment of patients with CLL are common, and one quarter of patients who held ibrutinib in this study experienced a disease flare. Resolution with resuming ibrutinib underscores the importance of awareness of this phenomenon for optimal management.
Awareness of this phenomenon among clinicians is critical to avoid associated patient morbidity and premature cessation of effective treatment with ibrutinib if the flare is misidentified as true progression of disease."
Some case studies
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
ncbi.nlm.nih.gov/pmc/articl...
Per this Chronic Lymphocytic Leukemia Treatment Algorithm 2022 healthunlocked.com/cllsuppo...
8. "A disease flare phenomenon, characterized by rapidly progressive symptoms and adenopathy and rarely histopathologic evidence of Richter transformation, may occur during interruptions in BTKi treatment, but particularly after stopping the covalent BTKi until the next line of therapy is started. We recommend continuing the BTKi during the transition period to next-line therapy, particularly through venetoclax ramp-up until the target dose is reached ."
With thanks to CLLerinOz and G-G of CLL/SLL Groups.io.
Note: Due to the need to increase awareness of this phenomenon, this is an unlocked post.
Neil